GlassScriptPhysician profile
Sanjay Ratnakant
NPI 1578569935
$2,418.18
in general payments reported to CMS, 2019-2025
31 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $519 · 2021: $399 · 2022: $98.70 · 2023: $317 · 2024: $222 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.89 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $600.74 | 2019-2023 | Tezspire, Fasenra |
| Harmony Biosciences LLC | $390.79 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $248.77 | 2023-2025 | Lumryz |
| Zoll Respicardia, INC. | $172.78 | 2025 | Remede System |
| Genentech USA, INC. | $81.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.48 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $65.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $64.17 | 2019-2024 | |
| Glaxosmithkline, LLC. | $62.36 | 2021-2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $58.00 | 2019-2020 | |
| Axsome Therapeutics, INC. | $52.99 | 2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $46.57 | 2020-2021 | |
| Grifols USA, LLC | $45.59 | 2020 | |
| Sunovion Pharmaceuticals INC. | $44.01 | 2019-2021 | |
| Philips North America LLC | $43.45 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $37.03 | 2020-2021 | |
| Gilead Sciences, INC. | $35.69 | 2021-2023 | |
| Amgen INC. | $34.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.86 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $24.93 | 2021 | |
| Advanced Respiratory, INC | $21.36 | 2021 | |
| Mallinckrodt Enterprises LLC | $20.77 | 2019 | |
| Ethicon INC. | $20.56 | 2022 | |
| Abbvie INC. | $20.21 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.12 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.50 | 2021 | |
| Allergan, INC. | $18.38 | 2019 | |
| Insmed, INC. | $15.44 | 2019 | |
| Shire North American Group INC | $14.31 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.25 | 2021 | |
| Veran Medical Technologies, INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Ratnakant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.